Vis børsmeldingen
Oslo, Norway, 20 May 2020
Nordic Nanovector ASA (OSE: NANO) announces that its Nomination Committee has
nominated Mr. Pål Erik Robinson for election as a member of the Nomination
Committee at the Company’s upcoming Annual General Meeting, as Mr. Olav
Steinnes, who has served as a member of the Nomination Committee since November
2014, has decided not to stand for re-election.
Mr. Robinson has for the last 18 years been owner and managing director of RO
Invest AS.
RO Invest AS is a private investment company, with an active ownership strategy,
focusing on listed and unlisted companies within the biotech- and technology
-space. Mr. Robinson has an MBA from INSEAD (1998/1999), a Master of Science in
Business (“Siviløkonom”) from the Norwegian School of Economics (NHH) (1990
-1993) and is Bachelor of Applied Science from the University of Oslo (1998
-1990).
Mr. Robinson, indirectly, through RO Invest AS, holds 800,000 shares in the
Company, equal to app. 1.2% of the total share capital.
Johan Christenson, MD, Chairman of Nordic Nanovector’s Nomination Committee
said: "On behalf of the Nomination Committee I would like to thank Mr. Steinnes
for his valuable contribution to the Company over the last years. I am pleased
to introduce Mr. Robinson who brings extensive experience as an investor in
various sectors that will be invaluable with regards to the future development
of the company.
For further information, please contact:
Johan Christenson, Chairman of the Nomination Committee of Nordic Nanovector ASA
Cell: +46 70 97 59 866
E-mail: johan.christenson@healthcap.eu
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
E-mail: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
E-mail: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.
Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting antibody-radionuclide-conjugate designed to advance the treatment of
non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet
medical need, representing a growing market forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin®
and intends to actively participate in the commercialisation of Betalutin® in
the US and other major markets.
Further information can be found at www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.
Kilde
